Adalimumab sustains clinical remission after 2 years of therapy in Crohn’s disease

Adalimumab sustains clinical remission after 2 years of therapy in Crohn’s disease

adalimumabStudies with Adalimumab and a TNF-α blockade shows promising results for Adalimumab therapy for joint pain. Joint pains have inflicted thousands of people worldwide. Age is a non-modifiable risk factor when it comes to degenerative bone disease. However, certain autoimmune joint diseases affect the young population as well. Juvenile idiopathic arthritis, ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis are just a few of the autoimmune joint diseases that affect people from all age groups. A naturally occurring cytokine, TNF-α causes our immune system to “overreact” with the ultimate goal of protecting our bodies from harmful agents but the aftermath of the battle leaves an undesirable trail mostly attributed to inflammation in virtually any part of the human body.

With TNF-α overproduction having several undesirable effects, studies on TNF-α blockade are wide and extensive. One of the most promising results of these studies produced the injectable protein, Adalimumab (Humira). In 2008, Adalimumab became the first fully human monoclonal antibody drug approved by the FDA for the treatment of degenerative joint diseases.

Recently, Adalimumab was put in the spotlight again for yielding positive clinical outcomes for the long term treatment of Crohn’s disease. A randomized double blind study conducted by R. Panaccione et al over a period of two years saw continued progress on the Inflammatory Bowel Disease Questionnaire completed by the participants. Parameter improvements were most apparent in the quality of life and reduced number of hospitalizations during the two year treatment period with 40 mg Adalimumab every other week.

With newer treatment modalities surfacing, issues with efficacy and safety of new drugs or old drugs with new indications, the pharmaceutical community recognizes the need for continuing the research work already started. As a member of this elite enterprise, LGM Pharma supplies Adalimumab CAS# 331731-18-1 and other Monoclonal Antibodies to global pharmaceutical companies involved in their R & D studies. Product quality, company reliability, and quality customer service sits on LGM Pharma’s core priorities.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service